2013
DOI: 10.1200/jco.2012.44.7524
|View full text |Cite
|
Sign up to set email alerts
|

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

Abstract: Most patients with relapsed or refractory PTCL have poor outcomes with short survival. Select patients with good PS have more favorable outcomes with standard chemotherapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

15
231
2
7

Year Published

2014
2014
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 348 publications
(260 citation statements)
references
References 15 publications
15
231
2
7
Order By: Relevance
“…Yet recent data from Mak et al did not indicate any differences in outcome between patients with various systemic PTCL subtypes at relapse, even systemic ALCL, who cannot undergo hematopoietic stem cell transplantation. 9 Altogether, these data further suggest that BV especially improves the outcome of ALCL patients at relapse compared to non-ALCL PTCL.…”
mentioning
confidence: 55%
See 1 more Smart Citation
“…Yet recent data from Mak et al did not indicate any differences in outcome between patients with various systemic PTCL subtypes at relapse, even systemic ALCL, who cannot undergo hematopoietic stem cell transplantation. 9 Altogether, these data further suggest that BV especially improves the outcome of ALCL patients at relapse compared to non-ALCL PTCL.…”
mentioning
confidence: 55%
“…Mathilde Lamarque, 1,2,3 Céline Bossard, 4 Adrien Contejean, 5,6 Pauline Brice, 6 Marie Parrens, 7 Steven Le Gouill, 8,9 Josette Brière, 10 Reda Bouabdallah, 11 …”
Section: 1112unclassified
“…4 In addition, similar to other peripheral T-cell lymphoma, relapsed ATLL is often refractory to salvage chemotherapies. 15 Taking these poor clinical outcomes into consideration, it is likely that early application of allo-HSCT for patients with ATLL will be able to improve the clinical outcome as in high-risk AML.…”
Section: Discussionmentioning
confidence: 99%
“…Current treatment strategies are inadequate and survival at relapse is extremely poor, especially in the transplant ineligible group. 74 Although a plethora of new drugs have been trialed in the relapse setting, progressive free survival and OS remain disappointing. The use of intelligent combinations combined with a biomarker-driven approach is likely to be a fruitful avenue of further research.…”
Section: Discussionmentioning
confidence: 99%